<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00381654</url>
  </required_header>
  <id_info>
    <org_study_id>AV-412-06-101</org_study_id>
    <nct_id>NCT00381654</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies</brief_title>
  <official_title>A Phase 1, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily Oral Administration of AV-412 in Patients With Refractory or Relapsed Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who&#xD;
      have not responded to standard therapy or surgical interventions, or who have experienced&#xD;
      relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose&#xD;
      for the treatment of solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although progress has been made, patients with malignancies often either progress after the&#xD;
      traditional approach of chemotherapy, surgery, or radiotherapy, or are not candidates for&#xD;
      these approaches because of the advances stage of disease. Novel therapies that may offer&#xD;
      greater potential than those currently available are urgently needed.&#xD;
&#xD;
      AV 412 is a potent inhibitor of human epidermal growth factor family receptor tyrosine&#xD;
      kinases (TKIs) and represents a growing class of anti-cancer agents. The recent introduction&#xD;
      of TKIs has opened the door to new approaches to cancer treatment in which the goals of&#xD;
      therapy are to halt disease progression, ameliorate symptoms, and improve patient quality of&#xD;
      life. AV412 may inhibit growth of solid tumors, with fewer and less debilitating side&#xD;
      effects.&#xD;
&#xD;
      This study is designed to determine the safety, tolerability and maximum tolerated dose of&#xD;
      daily oral administration of AV 412. Patients will be assigned to escalating drug dose&#xD;
      cohorts to determine the optimal dose. Evaluations to determine tolerability include PK, PD,&#xD;
      and the adverse events which occur during the course of study drug administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study did not meet pre-specified objectives.&#xD;
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety, tolerability, and dose-limiting toxicities (DLT), and determine the maximum tolerated dose (MTD) of AV-412 when administered once daily by the oral route for 4 weeks (4 weeks equals one dosing cycle)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetic (PK) profile of AV-412 in all patients. Extensive PK collection and assay to be performed in expanded MTD Cohorts</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate potential pharmacodynamic (PD) markers of AV-412 action, in expanded MTD Cohorts ONLY</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary evaluation of the antineoplastic activity of AV-412 (assessed by evidence and duration of disease stabilization or objective response, and time to disease progression)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral administration of AV-412</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AV-412</intervention_name>
    <description>Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for Inclusion:&#xD;
&#xD;
          1. ≥ 18 year old males or females&#xD;
&#xD;
          2. Documented measurable or evaluable solid tumor malignancy that is relapsed,&#xD;
             refractory, locally advanced, or metastatic&#xD;
&#xD;
          3. Patients entered to MTD Cohort B must have:&#xD;
&#xD;
               -  Histologically or cytologically confirmed NSCLC&#xD;
&#xD;
               -  No prior therapy with erlotinib, gefitinib, or any other EGFR-kinase inhibitor&#xD;
&#xD;
               -  Previously documented exon 19 deletion and/or exon 21 L858R mutations&#xD;
&#xD;
               -  Measurable disease according to RECIST&#xD;
&#xD;
          4. Disease that is currently refractory to, or not amenable to, standard therapy&#xD;
&#xD;
          5. Disease that is currently not amenable to surgical intervention, due to either medical&#xD;
             contraindications or nonresectability of the tumor&#xD;
&#xD;
          6. Karnofsky performance status ≥ 70%, life expectancy ≥ 3 months&#xD;
&#xD;
          7. No childbearing potential or use of effective contraception by all fertile male and&#xD;
             female patients, during the study and for 3 months after the last dose of study drug&#xD;
&#xD;
          8. Ability to give written informed consent&#xD;
&#xD;
        Criteria for Exclusion:&#xD;
&#xD;
          1. Pregnant or lactating women&#xD;
&#xD;
          2. Primary CNS malignancies; active CNS metastases&#xD;
&#xD;
          3. Hematologic malignancies (includes: leukemia, any form; lymphoma; and multiple&#xD;
             myeloma)&#xD;
&#xD;
          4. Active second malignancy or history of another malignancy within 2 years with the&#xD;
             exception of:&#xD;
&#xD;
               -  Treated, non-melanoma skin cancers&#xD;
&#xD;
               -  Treated CIS of the breast or cervix&#xD;
&#xD;
               -  Controlled, superficial bladder carcinoma&#xD;
&#xD;
               -  T1a or b prostate carcinoma involving &lt; 5% of resected tissue and PSA within&#xD;
                  normal limits (WNL)&#xD;
&#xD;
          5. Any of the following hematologic abnormalities:&#xD;
&#xD;
               -  Hemoglobin ≤ 9.0 g/dL&#xD;
&#xD;
               -  ANC &lt; 1,500 per mm3&#xD;
&#xD;
               -  Platelet count &lt; 100,000 per mm3&#xD;
&#xD;
          6. Any of the following serum chemistry abnormalities:&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 × the ULN&#xD;
&#xD;
               -  AST or ALT ≥ 3 × the ULN (≥ 5 × if due to hepatic involvement by tumor)&#xD;
&#xD;
               -  Serum albumin &lt; 2.5 g/dL&#xD;
&#xD;
               -  Creatinine ≥ 1.5 × ULN (or calculated CLCR &lt; 50 mL/min/1.73 m2)&#xD;
&#xD;
          7. Significant cardiovascular disease, including:&#xD;
&#xD;
               -  CHF requiring therapy&#xD;
&#xD;
               -  Ventricular arrhythmia requiring therapy&#xD;
&#xD;
               -  Any conduction disturbance (including patients with QTc interval prolongation &gt;&#xD;
                  0.47 sec, history of a severe arrhythmia, or history of a familial arrhythmia&#xD;
                  [eg, WPW])&#xD;
&#xD;
               -  Angina pectoris requiring therapy&#xD;
&#xD;
               -  LVEF &lt; 50% by MUGA or Echocardiogram&#xD;
&#xD;
               -  Uncontrolled HTN&#xD;
&#xD;
               -  MI within 6 months of study entry&#xD;
&#xD;
               -  NYHA &gt; Class I&#xD;
&#xD;
          8. Significant gastrointestinal abnormalities, including:&#xD;
&#xD;
               -  Requirement for IV alimentation&#xD;
&#xD;
               -  Prior surgical procedures affecting absorption&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  ≥Grade 2 diarrhea due to any etiology&#xD;
&#xD;
          9. Known history of significant ophthalmologic abnormalities, including:&#xD;
&#xD;
               -  Severe dry-eye syndrome&#xD;
&#xD;
               -  Keratoconjunctivitis sicca&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Severe exposure keratopathy&#xD;
&#xD;
               -  Disorders increasing risk for epithelium-related complications&#xD;
&#xD;
         10. Serious/active infection; infection requiring parenteral antibiotics&#xD;
&#xD;
         11. Inadequate recovery from prior antineoplastic therapy&#xD;
&#xD;
         12. Inadequate recovery from any prior surgical procedure; major surgical procedure within&#xD;
             2 weeks&#xD;
&#xD;
         13. Life-threatening illness or organ system dysfunction compromising safety evaluation&#xD;
&#xD;
         14. Psychiatric disorder, altered mental status precluding informed consent or necessary&#xD;
             testing&#xD;
&#xD;
         15. Inability to comply with protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Hidalgo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Justina L Martinez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitatrio Austral</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen S. Puparelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Médico Especializado Alexander Fleming</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Belén R. Viquiera, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Integral Oncológica Clara Campal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitatrio Austral</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Especializado Alexander Fleming</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://aveopharma.com</url>
    <description>Aveo Pharmaceutical, Inc home page</description>
  </link>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2006</study_first_posted>
  <last_update_submitted>September 30, 2011</last_update_submitted>
  <last_update_submitted_qc>September 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Tyrosine Kinases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MP 412</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

